These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 23239836)

  • 21. A comprehensive, longitudinal description of the in-hospital and post-discharge clinical, laboratory, and neurohormonal course of patients with heart failure who die or are re-hospitalized within 90 days: analysis from the EVEREST trial.
    Gheorghiade M; Pang PS; Ambrosy AP; Lan G; Schmidt P; Filippatos G; Konstam M; Swedberg K; Cook T; Traver B; Maggioni A; Burnett J; Grinfeld L; Udelson J; Zannad F
    Heart Fail Rev; 2012 May; 17(3):485-509. PubMed ID: 21932146
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influence of documented history of coronary artery disease on outcomes in patients admitted for worsening heart failure with reduced ejection fraction in the EVEREST trial.
    Mentz RJ; Allen BD; Kwasny MJ; Konstam MA; Udelson JE; Ambrosy AP; Fought AJ; Vaduganathan M; O'Connor CM; Zannad F; Maggioni AP; Swedberg K; Bonow RO; Gheorghiade M
    Eur J Heart Fail; 2013 Jan; 15(1):61-8. PubMed ID: 22968743
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of low body temperature and poor outcomes in patients admitted with worsening heart failure: a substudy of the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) trial.
    Payvar S; Spertus JA; Miller AB; Casscells SW; Pang PS; Zannad F; Swedberg K; Maggioni AP; Reid KJ; Gheorghiade M;
    Eur J Heart Fail; 2013 Dec; 15(12):1382-9. PubMed ID: 23858000
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In-Hospital Diuretic Agent Use and Post-Discharge Clinical Outcomes in Patients Hospitalized for Worsening Heart Failure: Insights From the EVEREST Trial.
    Mecklai A; Subačius H; Konstam MA; Gheorghiade M; Butler J; Ambrosy AP; Katz SD
    JACC Heart Fail; 2016 Jul; 4(7):580-588. PubMed ID: 27039131
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Response Prediction and Influence of Tolvaptan in Chronic Heart Failure Patients Considering the Interaction of the Renin-Angiotensin-Aldosterone System and Arginine Vasopressin.
    Kadota M; Ise T; Yagi S; Iwase T; Akaike M; Ueno R; Kawabata Y; Hara T; Ogasawara K; Bando M; Bando S; Matsuura T; Yamaguchi K; Yamada H; Soeki T; Wakatsuki T; Sata M
    Int Heart J; 2016 Jul; 57(4):461-5. PubMed ID: 27357439
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial.
    Gheorghiade M; Gattis WA; O'Connor CM; Adams KF; Elkayam U; Barbagelata A; Ghali JK; Benza RL; McGrew FA; Klapholz M; Ouyang J; Orlandi C;
    JAMA; 2004 Apr; 291(16):1963-71. PubMed ID: 15113814
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) program.
    O'Connor CM; Miller AB; Blair JE; Konstam MA; Wedge P; Bahit MC; Carson P; Haass M; Hauptman PJ; Metra M; Oren RM; Patten R; Piña I; Roth S; Sackner-Bernstein JD; Traver B; Cook T; Gheorghiade M;
    Am Heart J; 2010 May; 159(5):841-849.e1. PubMed ID: 20435194
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical profile and prognostic value of anemia at the time of admission and discharge among patients hospitalized for heart failure with reduced ejection fraction: findings from the EVEREST trial.
    Mentz RJ; Greene SJ; Ambrosy AP; Vaduganathan M; Subacius HP; Swedberg K; Maggioni AP; Nodari S; Ponikowski P; Anker SD; Butler J; Gheorghiade M
    Circ Heart Fail; 2014 May; 7(3):401-8. PubMed ID: 24737459
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tolvaptan Improves the Long-Term Prognosis in Patients With Congestive Heart Failure With Preserved Ejection Fraction as Well as in Those With Reduced Ejection Fraction.
    Imamura T; Kinugawa K
    Int Heart J; 2016 Sep; 57(5):600-6. PubMed ID: 27581675
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increased urine aquaporin-2 relative to plasma arginine vasopressin is a novel marker of response to tolvaptan in patients with decompensated heart failure.
    Imamura T; Kinugawa K; Fujino T; Inaba T; Maki H; Hatano M; Yao A; Komuro I
    Circ J; 2014; 78(9):2240-9. PubMed ID: 24954239
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Critical elements of clinical follow-up after hospital discharge for heart failure: insights from the EVEREST trial.
    Dunlay SM; Gheorghiade M; Reid KJ; Allen LA; Chan PS; Hauptman PJ; Zannad F; Maggioni AP; Swedberg K; Konstam MA; Spertus JA
    Eur J Heart Fail; 2010 Apr; 12(4):367-74. PubMed ID: 20197265
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relation of serum magnesium levels and postdischarge outcomes in patients hospitalized for heart failure (from the EVEREST Trial).
    Vaduganathan M; Greene SJ; Ambrosy AP; Mentz RJ; Fonarow GC; Zannad F; Maggioni AP; Konstam MA; Subacius HP; Nodari S; Butler J; Gheorghiade M;
    Am J Cardiol; 2013 Dec; 112(11):1763-9. PubMed ID: 24095030
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum Osmolality and Postdischarge Outcomes After Hospitalization for Heart Failure.
    Vaduganathan M; Marti CN; Mentz RJ; Greene SJ; Ambrosy AP; Subacius HP; Fonarow GC; Chioncel O; Bazari H; Maggioni AP; Zannad F; Konstam MA; Sato N; Gheorghiade M; Butler J;
    Am J Cardiol; 2016 Apr; 117(7):1144-50. PubMed ID: 26851146
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of arginine vasopressin with low atrial natriuretic peptide levels, left ventricular remodelling, and outcomes in adults with and without heart failure.
    Chirinos JA; Sardana M; Oldland G; Ansari B; Lee J; Hussain A; Mustafa A; Akers SR; Wei W; Lakatta EG; Fedorova OV
    ESC Heart Fail; 2018 Oct; 5(5):911-919. PubMed ID: 29969536
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical implications of QRS duration in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction.
    Wang NC; Maggioni AP; Konstam MA; Zannad F; Krasa HB; Burnett JC; Grinfeld L; Swedberg K; Udelson JE; Cook T; Traver B; Zimmer C; Orlandi C; Gheorghiade M;
    JAMA; 2008 Jun; 299(22):2656-66. PubMed ID: 18544725
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vasopressin-receptor antagonists in heart failure.
    Schweiger TA; Zdanowicz MM
    Am J Health Syst Pharm; 2008 May; 65(9):807-17. PubMed ID: 18436727
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum and urine responses to the aquaretic agent tolvaptan in hospitalized hyponatremic patients.
    Vaghasiya RP; DeVita MV; Michelis MF
    Int Urol Nephrol; 2012 Jun; 44(3):865-71. PubMed ID: 21607553
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differentiation of arginine vasopressin antagonistic effects by selective V2 versus dual V2/V1a receptor blockade in a preclinical heart failure model.
    Mondritzki T; Kolkhof P; Sabbah HN; Gheorghiade M; Fürstner C; Schmeck C; Siedentop H; Schaefer S; Truebel H
    Am J Ther; 2011 Jan; 18(1):31-7. PubMed ID: 21192248
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Temporal Changes in Postdischarge Mortality Risk After Hospitalization for Heart Failure (from the EVEREST Trial).
    Cook TD; Greene SJ; Kalogeropoulos AP; Fonarow GC; Zea R; Swedberg K; Zannad F; Maggioni AP; Konstam MA; Gheorghiade M; Butler J
    Am J Cardiol; 2016 Feb; 117(4):611-616. PubMed ID: 26742474
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vasopressin antagonism in heart failure: a review of the hemodynamic studies and major clinical trials.
    Urbach J; Goldsmith SR
    Ther Adv Cardiovasc Dis; 2021; 15():1753944720977741. PubMed ID: 33435837
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.